NCT04150497 2025-09-09Phase 1/2 Study of UCART22 in Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia (BALLI-01)Cellectis S.A.Phase 1/2 Recruiting52 enrolled
NCT00077961 2015-03-26Rituximab Plus CAMPATH in Patients With Relapsed/Refractory Low-Grade or Follicular, CD20-positive, B-cell NHLSanofiPhase 1/2 Terminated49 enrolled
NCT00051701 2015-03-05Phase I/II Study of CAMPATH in Patients With Relapsing or Refractory Non-Hodgkin's LymphomaSanofiPhase 1/2 Terminated61 enrolled